This protocol addresses patients with indolent or smoldering systemic mastocytosis (ISM/SSM) who present with neuropsychiatric symptoms — specifically headache, cognitive impairment, or depression. These manifestations define a distinct clinical subgroup requiring a targeted approach to symptom management.
The concurrent presence of headache, cognitive impairment, or depressed mood alongside underlying mast cell disease shapes management priorities. In ISM, treatment goals are primarily directed toward anaphylaxis prevention, symptom control, and osteoporosis treatment.
A second-line strategy involving sodium cromolyn is part of the management plan for this clinical scenario. Full details — including dosing schedule, timing, and the complete clinical algorithm — are contained in the structured protocol.
DOI: 10.1002/ajh.26962
Treatment goals for ISM patients are primarily directed toward anaphylaxis prevention/symptom control/osteoporosis treatment.
Sodium cromolyn
View source ↗